A new study argues for a revised clonal evolution model of cancer, incorporating genetic and non-genetic factors to improve understanding and treatment.
Like all living organisms, cancer cells are driven by the fundamental need to grow, survive, and reproduce. Although cancer's evolutionary underpinnings have been recognized since the 1950s, clinicians have been slow to apply the lessons of evolution to the fight against this deadly disease, which claimed 9.7 million lives worldwide in 2022 and remains the second-leading cause of death.
In a new study published in the journal Nature Reviews Cancer, Arizona State University researcher Carlo Maley and Lucie Laplane from the University of Paris Pantheon-Sorbonne review the prevailing theory of cancer evolution. The authors identify both practical and theoretical limitations of the clonal model of cancer evolution and propose revisions that could improve the model's accuracy and relevance.
The study suggests that the model could be improved by acknowledging that cancer cells inherit not only genetic mutations but also other traits that allow them to rapidly adapt to their environment — even without genetic alterations. Cancer cells are highly responsive to their surrounding environment, which can promote or suppress their growth. Further, cancer evolution often follows complex dynamics, leading to tangled and unpredictable growth patterns.
Rethinking the Clonal Evolution Model
Cancer biologists have traditionally defined a "clone" as a group of cells descending from a single ancestor cell and sharing the same genetic makeup. But cancer cells mutate so fast that no two cells have the same genetic makeup. The study proposes replacing the concept of a clone with a focus on the cell genealogies that record the history and define the structure of the cells in a tumor.
The value of an effective model lies in its ability to explain how and why cancers evolve and respond to therapy. By refining the clonal evolution model, the study paves the way for more effective cancer therapies that consider the full complexity of cancer cell evolution.
"Evolution is such a powerful idea that when we apply it to the cells in our bodies, it explains how we get cancer and why it is so hard to cure. But, like everything in the real world, it's complicated," Maley says. "We set out to address the complications that people have pointed out and show how they can be integrated into our theory of how cancer works."
Maley is a researcher in the Biodesign Center for Biocomputing, Security and Society, director of the Arizona Cancer Evolution Center, and a professor at ASU's School of Life Sciences.
His collaborator, Lucie Leplane, visited ASU for the research project, thanks to the generous support of the Center for Biology and Society and a grant from the McDonnell Foundation.
Expanding Evolutionary Cancer Theory
The clonal evolution theory of cancer suggests that cancer begins from a single cell that undergoes mutations, enabling it to grow and divide faster than normal cells. As this cell divides, some of its offspring may gain additional mutations that provide even greater advantages in survival and growth. Over time, this process leads to a population of cancer cells that are very diverse but driven by those that are most fit for survival and reproduction in their environment. This theory helps explain why cancers can be so challenging to treat — they continuously evolve, making them adaptable to various therapies and environments.
To address these issues, the researchers explore the limits of the current evolutionary cancer theory. A key challenge is expanding this theory to encompass all the ways cancer evolves, including the inheritance of more than just genes when cells divide and genetic material exchange among cells, as well as developing better methods to identify and track cancer cell variations.
Traditionally, it has been assumed that the DNA of cancer cells largely determines their behavior and progression. This includes how they grow, spread, and respond to treatments. The study challenges this view, highlighting other factors such as the influence of a cell's surrounding environment and epigenetic changes — chemical modifications that alter gene expression without changing the genetic sequence.
Another assumption is that the development of cancer can be traced like a tree, from one main ancestor cell branching out into all the cancer cells found in a tumor. That model implies a neat, predictable pattern of cancer growth. However, the study suggests this is not always the case. Cancer cells can merge (through cell fusion) or acquire traits from other cells. This could make the growth pattern of cancers more complex, resembling more of a network with multiple influences and paths.
Further, while clonal evolution was initially considered a continuous, gradual process, it has been shown to occur during stasis, gradual change, or sudden, punctuated bursts.
Conclusion and Treatment Implications
The clonal evolution model has already brought about a significant shift in how we view cancer, highlighting the disease's profoundly dynamic nature. This shift in perspective has helped discredit the search for a single "magic bullet" treatment and prompted changes in both research and treatment approaches.
Although the clinical impact of evolutionary theory has been limited so far, a range of evolutionary strategies for treatment has shown encouraging results, such as adaptive therapy, which can lead to dramatic improvements in time progression and overall survival.
Understanding the multifaceted nature of cancer evolution is critical for developing more effective treatments. The study suggests that targeting not only genetic mutations but also epigenetic changes and interactions with the surrounding cell environment could improve treatment outcomes.
By refining the clonal evolution model, the study paves the way for more effective cancer therapies that consider the full complexity of cancer cell evolution.
Reference: "The evolutionary theory of cancer: challenges and potential solutions" by Lucie Laplane, and Carlo C. Maley, 10 September 2024, Nature Reviews Cancer.
DOI: 10.1038/s41568-024-00734-2
News
Where do nanoparticles go once they enter the body?
New international best practice guidance, co-written at ANSTO, sets out how to measure where nanoparticles like titanium dioxide end up in the body and how long they remain. The guidance has been shared by [...]
Long-Acting HIV Shots Could Solve a Major Treatment Challenge for Young People
A major African trial suggests that changing how HIV treatment is delivered could significantly improve viral suppression in adolescents. Young people with HIV were more likely to keep the virus suppressed when they received [...]
WHO Factsheets – The top 10 causes of death
In 2023, the 10 leading causes of death accounted for 33 million deaths, or 54% of the total 61 million deaths worldwide. The top global causes of death, in order of total number of lives lost, [...]
Aging Cells May Be Hiding From the Immune System – Scientists Think They Know How
Your immune system is supposed to clear out damaged cells. Researchers may have found how some of them hide and linger as the body ages. Researchers led by Cedars-Sinai Health Sciences University have identified [...]
Your Voice May Reveal How Fast Your Brain Is Aging
Researchers have developed a machine-learning “speech clock” that estimates age from subtle patterns in how people speak and what they say. It is possible that people’s voices may contain certain signals of aging that [...]
Optogenetics Pioneers Win 2026 Nobel Prize in Physiology or Medicine
The 2026 Nobel Prize in Physiology or Medicine has been awarded to Peter Hegemann, Georg Nagel, and Karl Deisseroth for the development of optogenetics, a revolutionary technology that uses light to control individual neurons [...]
Molecular Manufacturing: The Future of Nanomedicine – From NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
What is ‘American Covid’ and how bad is it?
Cases of so-called ‘American Covid’ are on the rise in the UK. The strain is officially called XFG, or ‘Stratus’, and is the most common variant in North America, hence the name. It might soon [...]
Researcher at Russian plague laboratory dies of ‘unknown’ infection
Russian authorities have imposed "anti-epidemic measures" after a laboratory worker at an institute in Siberia dedicated to studying the plague and other infectious diseases died of a mysterious illness. The researcher, a 28-year-old female [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
A Surprising Brain Signal Could Explain Why Eating Less Protein Extends Lifespan
A new paper suggests that limiting protein intake triggers a coordinated response throughout the body that may help explain how protein restriction affects healthy aging. Animals respond to protein restriction, or reduced protein in [...]
Back and shoulder surgery is often worse than useless
Millions of operations should be scrapped SIX IN TEN Britons have surgery at some point. So do lots of Americans, at a cost of perhaps $500bn a year, a third of all spending on [...]
Cocaine plays with mind, hijacks brain circuit, drives increasingly rigid and repetitive behavior
Researchers have found that cocaine hijacks brain circuit, which to drive increasingly rigid and repetitive behavior. The brain circuit that normally participates in selecting natural mouth and face movements, but which becomes disproportionately engaged [...]
Injectable nanodevices could provide effective treatment for drug-resistant glioblastoma
The brain cancer glioblastoma is one of the most aggressive and treatment-resistant cancers known to medicine, carrying a median survival of just 12-15 months, even with the best available care. Now, researchers at the [...]
New Treatment Cuts “Bad” Cholesterol in Half for a Full Year
A single infusion of an experimental CRISPR-Cas9 therapy was reported to safely lower LDL cholesterol by 52.5% and triglycerides by 47.8%, as measured 12 months after treatment. What if one infusion could keep cholesterol [...]
Too Much RNA Can Drain a Cell’s Energy, Scientists Discover
A virus may cripple a cell’s power supply simply by producing too much of a molecule the cell needs to survive. New research from the Texas A&M College of Veterinary Medicine and Biomedical Sciences [...]
